Did You Know?

Editor’s Picks

Latest News

AvenCell Therapeutics to Report Phase 1a Results of First-in-Class Switchable Allogeneic CD123 CAR-T Therapy for AML in Late-Breaking oral presentation at EHA 2026

WATERTOWN, Mass. and DRESDEN, Germany, June 2, 2026 /PRNewswire/ -- AvenCell Therapeutics, a clinical-stage cell therapy company developing switchable CAR-T...

error: Content is protected !!